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Background: Nocturnal gastroesophageal reflux (nGER) has received increasing interest as
a predisposing factor for respiratory diseases and sleep disturbances. The possible role of
obstructive sleep apnea (OSA) contributing to nGER is of special interest. The aim of this study
was to explore the association between nGER and respiratory diseases, lung function and
symptoms of OSA.
Methods: Participants in the Burden of Obstructive Lung Disease (BOLD) initiative in Iceland
and Sweden, a random sample from the general population of 1325 adults aged 40þ (>70%
response rate), were compared by pre- and post-bronchodilator spirometry, answers to ques-
tionnaires about OSA and respiratory symptoms, health, and symptoms of GER.
Results: Altogether 102 (7.7%) reported nGER and 249 had used medication against GER. The
participants were divided into three groups: 1) No nGER (n Z 1040), 2) treated GER without
nGER (n Z 183) and 3) nGER (nZ 102). The nGER group had a significantly higher prevalence
of respiratory and OSA symptoms than subjects without nGER. The nGER group also had a higher
prevalence of COPD (GOLD stage 1þ), (25.0% vs. 15.6%) (p Z 0.02) and lower FEV1/FVC ratio
(95.9% vs. 98.9% of the predicted, pZ 0.01). These associations remained significant after ad-
justing for smoking, weight and other possible confounders. No independent association was
found between having treated GER and lung function, respiratory or OSA symptoms.l reflux; nGER, nocturnal GER; OSA, Obstructive sleep apnea; BMI, Body mass index; FEV1, Forced
vital capacity; PEF, Peak expiratory flow; COPD, Chronic obstructive pulmonary disease; ESS, Epworth
sitive airway pressure.
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increases the awareness of the evident association between nocturnal gastroesophageal
ory symptoms and diseases, as well as obstructive sleep apnea (OSA). There is also
vely affects lung function, which has only been vaguely reported before.
cations?
nGER in patients with respiratory symptoms and illnesses and the possibility of OSA
f OSA are more common among nGER patients, OSA needs to be assessed in these
patients. Successful treatment of nGER seems to diminish the negative respiratory outcomes.Introduction
Gastroesophageal reflux (GER) is a common condition, the
cardinal symptoms being heartburn and regurgitation.1,2
Prevalence numbers vary from 7 to 40%.1,3e5 Various respi-
ratory symptoms and conditions have been shown to co-occur
with GER, such as wheeze, rales, cough or phlegm.1,5 The
association between GER and lung function in the general
population, however, has only been studied to a small
degree, and it is therefore unclear if GER has any long term
consequences on lung function. A study published in 2010
showed that patients with recently diagnosed GER disease
had significantly lower forced expiratory volume in 1 s (FEV1)
and peak expiratory flow (PEF) than a control group.6
Both respiratory symptoms and obstructive sleep apnea
(OSA) have been shown to concur with GER even in a vicious
circle as OSA can increase the risk for nGER and vice versa.7,3
In this context, nocturnal GER (nGER) has been of special
interest.8 In our previous study on young adults with nGER,
both respiratory and OSA symptoms were increased among
nGER subjects.9 Also, treatment of OSA with nasal contin-
uous positive airway pressure (CPAP) has shown to improve
nGER.10,11 Many theories have been put forth about what
causes nGER in OSA patients, from repeated increases in
negative intrathoracic pressure, to transient lower esopha-
geal sphincter relaxation.12e14 However, the nature of this
association is still not thoroughly understood.14,15
Further studies are needed to clarify the nature of
respiratory symptoms in patients with nGER and comorbid
OSA.16 The aim of this investigation was to study nGER in
adults 40 years and older and its association to post-
bronchodilatory lung function, respiratory symptoms and
OSA-related symptoms in two Northern European centers.Material and methods
Study population
The study population was primarily invited to participate in
The Burden of Obstructive Lung Diseases (BOLD) initiative in
Iceland and Sweden, a multicentre international study
aiming to estimate the burden of COPD worldwide.17 The
present analyses are based on data from Reykjavik, Iceland,and Uppsala, Sweden, that has been described before.18
Briefly, using the national registries of inhabitants in both
countries, a random sample of adults aged 40 and over was
contacted and invited to participate in an examination that
included a structured interview, medical examination,
blood sample and a spirometry. The study was approved by
the local ethics committees (National Bioethics Committee
of Iceland: 04-080; Swedish Research Council: 2006/146).
Data collected and definitions
Questionnaires
As a part of the BOLD study protocol, all participants came
to the outpatient clinic of the respective hospitals in
Uppsala and Reykjavik where they answered equivalent
questionnaires on GER, symptoms of OSA, the Epworth
sleepiness scale, respiratory symptoms, smoking, health
status, medication use and other health related issues.17e19
The questionnaires had in previous studies been translated
from English into Icelandic and Swedish, and then back-
translated to check for accuracy. Trained and certified
staff administered the questionnaire.
Gastroesophageal reflux
Participants reporting heartburn once a week or more after
going to bed were considered to have nGER.9 Those reporting
use of medication against heartburn during the preceding
three months were defined as having GER treatment. Based
on these data the participants were categorized into three
groups: (a)NonGERandnoGERtreatment, called“NonGER”;
(b) GER treatment but no nGER, called “Treated GER”; (c)
nGER with or without GER treatment, called “nGER”.
Diabetes, hypertension and body mass index
The participants were defined as having hypertension or
diabetes if they reported doctor-diagnosed hypertension or
diabetes and were using appropriate medication. Height
and weight were measured by standardized methods. Body
mass index (BMI) was calculated as weight divided by
squared height.
Respiratory and OSA-related symptoms
The participants were asked whether they had experienced
a number of respiratory symptoms such as cough, phlegm
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smoking history, by which participants were divided into
smokers, ex-smokers and never-smokers. The OSA-related
questions included self-reported snoring, apneas, daytime
sleepiness and the Epworth sleepiness scale.18 Those
reporting either coughing most days for up to three months
each year, having phlegm most days for up to three months
each year, any wheeze for the last 12 months or shortness
of breath when hurrying were classified as having “any
respiratory symptom”. Those with observed snoring or
daytime sleepiness more than twice a week, or with
observed apneas once a week or more, were classified as
having “any OSA symptom”.
Spirometry
Trained and certified technicians performed spirometry
according to ATS criteria17 (EasyOne spirometer; ndd Med-
izintechnik; Zurich, Switzerland) as described before.20
Briefly, FEV1 and forced vital capacity (FVC) values were
obtained by spirometry. Pre- and post-bronchodilator tests
were performed, with separate measurements performed
before and after 15 min after two puffs of salbutamol
(200 mg). The primary reference equations used by BOLD
were derived from the third United States National Health
and Nutrition Examination Survey (NHANES III) for adult
Caucasian men and women.21 COPD was defined by
spirometry as a post-bronchodilatory FEV1/FVC < 0.70,
17 or
as being below the age-adjusted lower limit of normality
(LLN) in post-bronchodilatory FEV1/FVC.
21 Subjects with
COPD were grouped into stages I to IV based on FEV1/FVC
and FEV1.
22
Statistical analyses
All statistics were calculated with STATA 11.0 version
intercooled for Windows (Stata Corporation, CollegeFigure 1 Venn diagram of subjects withStation, Texas). Associations between nGER status and
symptoms were analyzed by a chi square test and logistic
regression, while associations between nGER and contin-
uous variables were analyzed with linear regression.
Multiple logistic and linear regressions were used to
estimate differences between the groups, adjust for
center, age, gender, BMI and smoking history, and do
interaction analyses. A p-value of <0.05 was defined as
being statistically significant.
Results
Study groups’ characteristics and prevalence of
nGER
Of the 1325 subjects included in the analysis, 183 individ-
uals were on GER medication and did not report nGER
symptoms (13.8%), and 102 (7.7%) reported nGER, whereof
66 of them were on medication against GER (64.7%) (Fig. 1).
The three groups were comparable regarding age, gender
and diabetes (Table 1). Hypertension and cigarette smoking
were significantly more common in the GER treated group,
and BMI was higher in that same group (Table 1).
Respiratory and obstructive sleep apnea symptoms
Subjects with nGER had a higher prevalence of respiratory
symptoms than subjects without GER (Table 2, Fig. 2).
Symptoms of OSA were more common in the treated GER
and nGER groups (Table 2, Fig. 2). The group with nGER had
the highest ESS score, and the highest prevalence of
daytime sleepiness and observed apneas of the three
groups. The prevalence of snoring was highest in the nGER
group, although not statistically significant. The associationGER treatment, nocturnal GER or both.
Table 1 Population characteristics (mean  SD and %).
No nGER (n Z 1040) Treated GER (n Z 183) p-value* Nocturnal GER (n Z 102) p-value*
Age, years 57  12 59  11 0.17 57  11 0.68
Male gender 53.5 47.5 0.14 53.9 0.94
Hypertension 29.8 41.5 0.002 28.4 0.77
Diabetes 4.5 5.0 0.81 6.9 0.30
BMI 27.1  4.5 29.0  5.3 <0.001 28.0  4.8 0.06
Smoking: 0.005 0.58
Never 43.0 32.2 39.2
Former 42.0 44.8 42.2
Current 15.0 23.0 18.6
BMI <0.001 0.401
<20 2.0 0.6 1.0
20e25 31.5 23.5 27.5
25e30 44.7 38.8 43.1
>30 21.7 37.2 28.4
SD Z Standard Deviation, GER Z Gastroesophageal Reflux.
Numbers are shown in bold when difference is significant (p < 0.05).
*p-value calculated with “No nGER” as a reference group.
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statically significant after adjustment for center, sex, age,
BMI and smoking history (Table 3).Lung function
COPD, as diagnosed by post-bronchodilator spirometry
(FEV1/FVC < 0.70 or below LLN),
17,20 was significantly
more common in the group with nGER (Table 4). Subjects
with treated GER had a significantly lower FEV1, while
subjects with nGER had a significantly lower FEV1/FVC
than subjects without GER (Table 4). The association
between treated GER and FEV1 lost its statistical signifi-
cance after adjusting for center, age, gender, smoking
history and BMI, while the other associations remained
significant (Table 5).Table 2 Respiratory and OSA symptoms (mean  SD and %).
No nGER
(n Z 1040)
Tr
(n
Respiratory symptoms:
Coughs most days at least 3 mo/yr 9.3 10
Phlegm most days at least 3 mo/yr 9.6 9.
Wheezing during the last 12 mo 21.9 32
Wheezing and shortness of breath
during the last 12 mo
6.1 9.
Attacks of breathlessness after
exercise during the last 12 mo
18.8 29
Obstructive sleep apnea symptoms:
Loud snoring  3 nights a week 22.8 23
Observed apneas  1 night a week 5.1 10
Daytime sleepiness  3 days a week 20.5 26
Epworth sleepiness scale 5.9  3.9 6.
SD Z Standard Deviation, mo Z Month, yr Z Year, GER Z Gastroeso
Numbers are shown in bold when difference is significant (p < 0.05).
*p-value calculated with “No nGER” as a reference group.Interactions
Interaction analyses were done while simultaneously
adjusting for center, age, gender, smoking history and BMI.
These analyses showed the association between nGER and
OSA symptoms was stronger in subjects from Reykjavı´k than
from Uppsala (OR (95% CI): 3.60 (1.86e7.00) vs. 1.42
(0.81e2.49), pinteractionZ 0.04). Also, this same association
was stronger among women than men (OR (95% CI): 3.55
(1.86e6.78) vs. 1.42 (0.80e2.51), pinteraction Z 0.04).
There was a significant difference in the association
between nGER and FEV1 between subjects with a normal
BMI (20e25) and obese subjects (>30), showing that among
normal weight subjects, those with nGER had significantly
lower FEV1 than those without GER, while no significant
association of this sort was found among obese subjects
(coef. (95% CI): 8.10 (14.51, 1.70) vs. 3.62 (2.44,eated GER
Z 183)
p-value* Nocturnal GER
(n Z 102)
p-value*
.9 0.48 15.7 0.04
3 0.91 19.6 0.002
.2 0.002 42.2 <0.001
9 0.06 22.6 <0.001
.7 0.01 27.9 0.15
.5 0.83 30.7 0.07
.0 0.01 10.8 0.02
.2 0.08 42.2 <0.001
2  3.7 0.29 6.9  4.6 0.18
phageal Reflux.
Figure 2 Comparison between the study groups regarding
any respiratory or OSA symptom.
Symptoms of nGER, OSA and lung function: An epidemiological study 4639.67), pinteraction Z 0.01). Finally, the association between
nGER and lower FEV1/FVC was stronger among men than
women (coef. (95% CI): 5.67 (8.52, 2.82) vs. 0.13
(3.11, 2.85), pinteraction Z 0.007).
No interactions were found in relation to smoking or age.
Discussion
The findings of this population-based study showed that
nocturnal GER is associated with both respiratory and OSA
symptoms. Nocturnal GER was also associated with a lower
FEV1/FVC ratio and a significantly higher proportion ful-
filling the spirometric criteria for COPD. These associations
were much weaker in the treated GER group.
The prevalence of nGER in the general population 40
years and older was almost 8%. In our previous study on
young adults using the same criteria for nGER (age range
20e48 years), it was 4.6%,9 which might suggest an increase
in prevalence with increasing age. However, since the mean
age was not different between subjects with or without
nGER in either study, and no difference in nGER prevalence
was found between age groups in the current study (data
not shown), this rather suggests an increase in the overall
prevalence of nGER from 1990 to 1993 to 2004e2006. A
possible reason for this is the 3.5 points’ higher average BMITable 3 Multiple logistic regression on any respiratory sympto
gender, smoking history and BMI (data on center omitted).
Any respiratory symptom (OR (95% CI))
No nGER 1
Treated GER 1.38 (0.99e1.91)
Nocturnal GER 2.40 (1.56e3.72)
Male gender 1.00 (0.79e1.27)
Age (per year) 1.01 (1.00e1.03)
Never smoker 1
Former smoker 1.22 (0.95e1.56)
Current smoker 2.85 (2.03e3.99)
BMI <20 0.99 (0.46e2.71)
BMI 20e25 1
BMI 25e30 1.32 (1.01e1.74)
BMI >30 1.78 (1.30e2.43)
ORZ Odds Ratio, CIZ Confidence Interval, OSAZ Obstructive Sleep
Numbers are shown in bold when difference is significant (p < 0.05).in the current study population. Also, as 24.4% had a BMI
above 30, high prevalence of obesity among people 40 years
and older was a particularly worrying finding given the
harmful association between BMI, nGER and the findings of
our study.
A major finding of this study was the significantly lower
FEV1/FVC ratio in subjects with nGER compared to the
subjects without GER. Also, among normal weight subjects,
those with nGER had a significantly lower FEV1 than those
without GER. This association was not seen among the
obese subjects. However, as obesity is a common risk factor
for both GER and lower FEV1,
23 it could be indicative of an
actual relationship between nGER and lower FEV1 to see
this association in the normal weight subjects of our study
population. This is not the first study to find a decrease in
the pulmonary function of GER or nGER patients, although
arguably the largest one until now. A study of US military
veterans with reflux esophagitis found COPD, as well as
many other respiratory diseases, to be more common than
in a comparable control group.24 Mise et al. found a signif-
icant decrease in FEV1 and PEF in 32 patients with GER, as
well as a lower pH and higher lactate dehydrogenase in
bronchoalveolar aspirates, indicative of tissue damage.6 In
addition, patients with erosive GER disease have been
found to have worse pulmonary function than those with
non-erosive GER disease.25
Symptoms of chronic bronchitis and asthma were more
common in nGER subjects than in those without GER. This is
in accordance with results from other studies, which show
an association of GER with chronic cough, asthma and
various upper respiratory tract symptoms.2,9,24,26 The
before mentioned findings of Mise et al. further support
possible causal relationships in these associations, but even
so, they need to be studied further.6
Our study shows that the nGER group had more OSA
symptoms and more often symptoms of excessive daytime
sleepiness than the “no nGER” group, even after adjusting
for common risk factors such as obesity. This is in agree-
ment with most former studies.9,11,27,28 One notable finding
we have not seen reported before was the stronger asso-
ciation between OSA symptoms and nGER among women
than men, even after the common adjustments. We werem and any OSA symptom between GER groups, center, age,
p-value Any OSA symptom (OR (95% CI)) p-value
1
0.05 1.28 (0.92e1.79) 0.14
<0.001 2.11 (1.37e3.23) 0.001
0.99 1.50 (1.19e1.90) 0.001
0.003 0.99 (0.98e1.00) 0.12
1
0.11 1.33 (1.03e1.71) 0.03
<0.001 1.92 (1.37e2.69) <0.001
0.98 0.84 (0.31e2.25) 0.73
1
0.04 1.47 (1.11e1.95) 0.01
<0.001 1.67 (1.22e2.30) 0.002
Apnea, GERZ Gastroesophageal Reflux, BMIZ Body Mass Index.
Table 4 Lung function (mean  SD and %).
No nGER
(n Z 1040)
Treated GER
(n Z 183)
p-value* Nocturnal GER
(n Z 102)
p-value*
FEV1/FVC below LLN:
Stage 1 9.4 10.3 0.72 18.8 0.01
Stage 2 (þFEV1 < 80%
pred.)
5.4 7.4 0.31 10.4 0.04
FEV1/FVC < 0.70:
Stage 1 15.6 18.9 0.27 25.0 0.02
Stage 2 7.0 9.7 0.20 10.4 0.16
FEV1 (% pred.)
a 94.8  15.8 91.9 17.3 0.02 92.2  17.5 0.13
FVC (% pred.)a 95.5  13.4 93.6  14.1 0.09 95.5  14.6 0.97
FEV1/FVC (% pred.)
a 98.9  9.8 97.4  11.1 0.08 95.9 12.0 0.01
SD Z Standard Deviation, GER Z Gastroesophageal Reflux, FEV1 Z Forced Expiratory Volume in One Second, FVC Z Forced Vital
Capacity.
Numbers are shown in bold when difference is significant (p < 0.05).
*p-value calculated with “No nGER” as a reference group.
a Post-bronchodilator value.
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difference.
There is an ongoing debate whether GER and OSA are
causally linked. Some have pointed out that since obesity is
a common risk factor for OSA and GER and the two condi-
tions are rather common, it can be difficult to prove an
association between the two conditions.29 Also, impaired
quality of sleep and daytime sleepiness can be caused by
both OSA and nGER, making the differential diagnosis more
complicated.27 However, nasal CPAP treatment for OSA
also significantly reduces the occurrence of nGER,
supportive of an actual association between OSA and
nGER.10,11 Also, other symptoms more specific of OSA, such
as apneas, are more common in patients with nGER, as our
study has shown. We therefore interpret our results as
a further indication of a close association between nGER
and OSA.
In the present cross-sectional analysis sleep-related and
respiratory symptoms as well as COPD were less common inTable 5 Multiple linear regression analysis for FEV1 and FEV1/FV
and BMI.
FEV1 (coef. (95% CI)) p-
No nGER 0
Treated GER 1.46 (4.01, 1.08) 0.
Nocturnal GER 2.48 (5.75, 0.79) 0.
Male gender 0.90 (0.86, 2.67) 0.
Age (per year) 0.14 (0.22, 0.06) <
Never smoker 0
Former smoker 3.01 (4.91, 1.11) 0.
Current smoker 6.39 (8.94, 3.84) <
BMI <20 10.54 (17.50, 3.59) 0.
BMI 20e25 0
BMI 25e30 0.53 (2.62, 1.56) 0.
BMI >30 5.43 (7.80, 3.05) <
coef. Z Correlation Coefficient, CI Z Confidence Interval, FEV1 Z
Capacity, GER Z Gastroesophageal Reflux, BMI Z Body Mass Index.
Numbers are shown in bold when difference is significant (p < 0.05).subjects with treated GER than the nGER group, thus indi-
cating that GER medication might be beneficial against
respiratory symptoms and sleep impairments in nGER
patients. Other studies have shown mixed results as to
whether or not medical GER treatment is beneficial for
patients with GER-related respiratory symptoms.26,30,31
However, the endpoints have differed between studies, as
well as methods and study time. A review by Coughlan et al.
on GER treatment in adult asthmatics implies that GER
treatment has little effect on their respiratory illness.31
However, more than half of the studies in this review had
a treatment period of six weeks or less, and therefore it is
not surprising the benefit was small. In fact, the studies
with a longer treatment time showed more benefit than the
others. As GER is usually a chronic condition with high
prevalence and low incidence,32 we can assume a large
proportion of those on GER treatment in our study have
been so for at least a few months. This might explain the
positive trend of our study, regarding the efficacy ofC between GER groups, center, age, gender, smoking history
value FEV1/FVC (coef. (95% CI)) p-value
0
26 1.10 (2.70, 0.50) 0.18
14 3.18 (5.25, 1.12) 0.003
32 0.96 (0.14, 2.07) 0.09
0.001 0.13 (0.18, 0.08) <0.001
0
002 2.77 (3.96, 1.57) <0.001
0.001 5.20 (6.80, 3.60) <0.001
003 4.25 (8.79, 0.29) 0.07
0
62 2.21 (0.89, 3.52) 0.001
0.001 2.90 (1.41, 4.39) <0.001
Forced Expiratory Volume in One Second, FVC Z Forced Vital
Symptoms of nGER, OSA and lung function: An epidemiological study 465treatment. Further randomized controlled trials with
longer treatment time are therefore needed before any
definitive conclusions can be made on this subject.
The key strengths of this study were the high number of
participants and the relatively high response rate. The
quality of the post-bronchodilator spirometries, carried out
by specially trained professionals, further increased the
quality of this study. Even so, a few methodological issues
need to be discussed. First, our definition of the nGER groups
was based on self-reported heartburn, which has up to 80%
sensitivity and 60% specificity,1,33 but isn’t diagnostic. To
minimize the incidence of false positive values resulting
from this, we therefore confined ourselves to those report-
ing heartburn at least once a week, which is generally
accepted as a reasonably specific marker for GER
disease.32,34 Second, the analysis of OSA symptoms is only
based on subjective measurements, while the analysis of
respiratory illnesses is based on objective measurements as
well. Therefore, the analysis on OSA symptoms is somewhat
weaker. Third, the definition of GER treatment might be too
loose, since it does not differentiate between regular or p.n.
usage, or between different types of medications. There-
fore, subjects on minimal treatment were categorized as
having GER treatment, increasing the number of subjects in
the treated GER group. However, this also served to purify
the group without GER, making it a better reference group.
Fourth, the use of two languages carries the risk of
a translation bias. However, we consider this risk to be
small, as the questions were all checked via back-
translation and tested for translation bias. The questions
regarding nGER were based on a former, thoroughly vali-
dated questionnaire.9 Finally, when studying many vari-
ables as in this study, the risk of a type I error must be
considered. However, since there is a trend in the many
positive results, where the symptom prevalence increased
in the study groups similarly for various symptoms, the risk
of a type I error must be considered small.
The results of this study suggested that nGER may be of
clinical relevance in patients with OSA and in patients with
respiratory symptoms. The evident decrease in pulmonary
function associated with nGER also calls out for further
studies on the association, and on the role of antireflux
therapy in this context.Acknowledgments
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